Search

Search Constraints

You searched for: Author/Creator Airey, David C.

Search Results

1. [P3–242]: PLASMA TOTAL TAU, COGNITIVE DECLINE, AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY ON AGING. (1st July 2017)

2. Gene Expression and Pharmacodynamic Changes in 1, 760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Issue 3 (27th February 2017)

3. Gene Expression and Pharmacodynamic Changes in 1, 760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Issue 3 (March 2017)

4. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population‐based elderly cohort. Issue 12 (16th July 2016)

5. O2‐05‐04: PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM. (1st July 2019)

6. P3‐152: Levels of TAU Protein in Plasma are Associated with Neurodegeneration and Cognitive Function in a Population‐Based Elderly Cohort. (1st July 2016)

8. Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography. Issue 8 (4th April 2018)

9. Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study. Issue 8 (13th February 2021)

10. The impact of cerebrovascular disease on blood‐based biomarkers of Alzheimer's disease. (31st December 2021)